C.R. Bard Inc. has announced that the results of its RESILIENT study were published recently in Circulation: Cardiovascular Interventions. The results show that Bard’s LifeStent Vascular Stent, currently the only stent approved by the FDA for use in the Femoral and Proximal Popliteal arteries, can prevent narrowing of these arteries when used during percutaneous transluminal angioplasty (PTA).
From the press release:
In the prospective, randomized, controlled, multi-center trial, 206 patients who required treatment for lesions up to 15cm received either PTA alone or PTA and a LifeStent® Vascular Stent. At six months post procedure, freedom from target lesion revascularization (TLR) was significantly better for the LifeStent® Vascular Stent group (98.5 percent) compared to the PTA group (52.6 percent). Similarly, freedom from TLR at 12 months remained significantly better for patients treated with a LifeStent® Vascular Stent (87.3 percent) compared to patients treated with PTA (45.1 percent).
Press release: TRIAL DATA DEMONSTRATES BARD LifeStent® VASCULAR STENT IS SUPERIOR TO ANGIOPLASTY FOR LESIONS IN SUPERFICIAL FEMORAL ARTERY AND PROXIMAL POPLITEAL ARTERY…
Product page: LifeStent® Vascular Stent